CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5404.38M
Enterprise Value 3266.52M
Trailing P/E N/A
Forward P/E 1-5.93
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)238.43
Price/Book (mrq)2.85
Enterprise Value/Revenue 3157.15
Enterprise Value/EBITDA 6-6.64

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3-26.72%
S&P500 52-Week Change 38.02%
52 Week High 336.95
52 Week Low 314.33
50-Day Moving Average 316.32
200-Day Moving Average 321.58

Share Statistics

Avg Vol (3 month) 367.42k
Avg Vol (10 day) 337.81k
Shares Outstanding 524.2M
Float 7.7M
% Held by Insiders 15.65%
% Held by Institutions 198.49%
Shares Short (Sep. 30, 2019) 41.97M
Short Ratio (Sep. 30, 2019) 422.77
Short % of Float (Sep. 30, 2019) 423.25%
Short % of Shares Outstanding (Sep. 30, 2019) 48.14%
Shares Short (prior month Aug. 30, 2019) 42M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 31, 2018
Most Recent Quarter (mrq)Jun. 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,410.97%

Management Effectiveness

Return on Assets (ttm)-22.24%
Return on Equity (ttm)-35.76%

Income Statement

Revenue (ttm)1.7M
Revenue Per Share (ttm)0.07
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-22.05M
EBITDA -40.11M
Net Income Avi to Common (ttm)-37.53M
Diluted EPS (ttm)-1.62
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)144.97M
Total Cash Per Share (mrq)5.99
Total Debt (mrq)5.9M
Total Debt/Equity (mrq)4.16
Current Ratio (mrq)19.07
Book Value Per Share (mrq)5.87

Cash Flow Statement

Operating Cash Flow (ttm)-31.03M
Levered Free Cash Flow (ttm)-21.36M